RE:RE:RE:RE:RE:Share buyback impactThe market just stinks for drug deals right now and has for some time. I’ve watched GUD, CPH, and RX all struggle to deploy capital over the past few years and it didn’t appear to be changing. Gud May have the right approach but it’s going to take another decade before they fully deploy their massive cash reserve. Meanwhile the other players all fight and likely over bid for scrap in-licensing deals. None of the companies appeal to me unless they merge. Rx is basically a one trick pony but is quite profitable. Cph is the same with a slightly better pipeline but a more dire patent cliff and worse balance sheet. Gud is basically just a giant Mo aunt sun of cash. Seems to me they should band together and stop fighting amounts each other for crummy drug deals.